SynthesisHepatology communications2026
Impact of body composition on clinical outcomes in patients with hepatocellular carcinoma: A systematic review and meta-analysis.
Synthesis in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAbnormalities in body composition are common in patients with hepatocellular carcinoma (HCC); however, their impact across different treatment modalities remains poorly understood. We systematically reviewed the prognostic value of body composition in patients with HCC, stratified by curative, locoregional, and systemic therapies.
methodsFollowing PRISMA 2020 guidelines, we searched PubMed, Embase, the Cochrane Library, and Web of Science (January 2015-March 2025) for studies reporting associations between CT/MRI or bioelectrical impedance analysis (BIA)-assessed body composition and outcomes in HCC.
resultsNinety-two studies were included (35 curative, 10 locoregional, 39 systemic, 8 mixed). Sarcopenia prevalence ranged from 6.4% to 62.8% (median study-level prevalence 38%-50% depending on treatment stratum). Sarcopenia independently predicted worse overall survival across all strata: curative (HR 1.52-3.76), locoregional (HR 1.72-2.51), and systemic therapies (HR 1.34-2.20). Sarcopenic obesity conferred the highest risk in the curative setting (HR up to 3.15). In systemic therapy, myosteatosis independently predicted mortality (HR 1.45-2.01), whereas visceral adiposity was protective (HR 0.56-0.66). In a random-effects meta-analysis of 44 studies, sarcopenia was associated with a pooled HR of 1.85 (95% CI 1.75-1.94; I2=0%), with consistent effects across curative (HR 1.86), locoregional (HR 2.10), and systemic strata (HR 1.71). Sarcopenia also predicted recurrence after curative treatment (pooled HR 1.71, 95% CI 1.61-1.82; k=14).
conclusionsSarcopenia predicts mortality in HCC, independently of treatment modality. Visceral adiposity appears detrimental after curative treatment but may be paradoxically protective during systemic therapy. Body composition should be integrated into clinical decision-making in HCC, though a clear consensus on measurement standardization is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.